Expression of fibroblast growth factor receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer

International Journal of Oncology

Volumn 36, Issue 2, 2010, Pages 331-340

  Kawase, Rieko ^a   Ishiwata, Toshiyuki ^a   Matsuda, Yoko ^a   Onda, Munehiko ^a   Kudo, Mitsuhiro ^a   Takeshita, Toshiyuki ^a   Naito, Zenya ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cervical intraepithelial neoplasia CIN; Fibroblast growth factor receptor 2 IIIc FGFR2 IIIc; Immunohistochemistry; In situ hybridization analysis; Uterine cervical cancer

Indexed keywords

COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2 IIIC; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; BLOTTING, WESTERN; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 75449096965     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000504     Document Type: Article

References (40)

1. Pectasides D, Kamposioras K, Papaxoinis G and Pectasides E: Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 34: 603-613, 2008.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
3. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
4. Wong AS, Leung PC and Auersperg N: Hepatocyte growth factor promotes in vitro scattering and morphogenesis of human cervical carcinoma cells. Gynecol Oncol 78: 158-165, 2000.
5. Kurban G, Ishiwata T, Kudo M, Yokoyama M, Sugisaki Y and Naito Z: Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. Oncol Rep 11: 987-991, 2004.
6. Van Trappen PO, Steele D, Lowe DG, et al: Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201: 544-554, 2003.
7. Kuramoto H, Hongo A, Liu YX, et al: Immunohistochemical evaluation of insulin-like growth factor I receptor status in cervical cancer specimens. Acta Med Okayama 62: 251-259, 2008.
8. Dai H, Holm R, Kristensen GB, Abeler VM, Borresen-Dale AL and Helland A: Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas. Anal Cell Pathol 23: 45-49, 2001.
9. Mayer TJ, Frauenhoffer EE and Meyers AC: Expression of epidermal growth factor and platelet-derived growth factor receptors during cervical carcinogenesis. In Vitro Cell Dev Biol Anim 36: 667-676, 2000.
10. Kuemmel S, Thomas A, Landt S, et al: Circulating vascular endothelial growth factors and their soluble receptors in preinvasive, invasive and recurrent cervical cancer. Anticancer Res 29: 641-645, 2009.
11. Mathur SP, Mathur RS, Gray EA, et al: Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A. Gynecol Oncol 98: 467-483, 2005.
12. Dobbs SP, Brown LJ, Ireland D, et al: Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Ann Diagn Pathol 4: 286-292, 2000.
13. Fujimoto J, Ichigo S, Hori M, Hirose R, Sakaguchi H and Tamaya T: Expression of basic fibroblast growth factor and its mRNA in advanced uterine cervical cancers. Cancer Lett 111: 21-26, 1997.
14. Hagemann T, Bozanovic T, Hooper S, et al: Molecular profiling of cervical cancer progression. Br J Cancer 96: 321-328, 2007.
15. Mathur RS and Mathur SP: Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers. Gynecol Oncol 97: 206-213, 2005.
16. Mitsuhashi A, Suzuka K, Yamazawa K, Matsui H, Seki K and Sekiya S: Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 103: 724-730, 2005.
17. Yang YC, Wang KL, Su TH, et al: Concurrent cisplatin-based chemoradiation for cervical carcinoma: tumor response, toxicity and serum cytokine profiles. Cancer Invest 24: 390-395, 2006.
18. Lebrecht A, Ludwig E, Huber A, et al: Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol Oncol 85: 32-35, 2002.
19. Itoh N and Ornitz DM: Evolution of the Fgf and Fgfr gene families. Trends Genet 20: 563-569, 2004.
20. Jaye M, Schlessinger J and Dionne CA: Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1135: 185-199, 1992.
21. Mohammadi M, Olsen SK and Ibrahimi OA: Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16: 107-137, 2005.
22. Eswarakumar VP, Lax I and Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149, 2005.
23. Miki T, Bottaro DP, Fleming TP, et al: Determination of ligandbinding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 89: 246-250, 1992.
24. Oltean S, Sorg BS, Albrecht T, et al: Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 103: 14116-14121, 2006.
25. Yan G, Fukabori Y, McBride G, Nikolaropolous S and McKeehan WL: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13: 4513-4522, 1993.
26. Dutt A, Salvesen HB, Chen TH, et al: Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105: 8713-8717, 2008.
27. Katoh Y and Katoh M: FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). Int J Mol Med 23: 307-311, 2009.
28. Katoh M: Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 33: 233-237, 2008.
29. Hudelist G, Czerwenka K, Singer C, Pischinger K, Kubista E and Manavi M: cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study. Cancer Genet Cytogenet 158: 35-42, 2005.
30. Chopra V, Dinh TV and Hannigan EV: Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 16: 152-159, 1998.
31. Cho K, Ishiwata T, Uchida E, et al: Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. Am J Pathol 170: 1964-1974, 2007.
32. Ishiwata T: Immunohistochemical and in situ hybridization analysis of lumican in colorectal carcinoma. In: Immunohistochemistry and In Situ Hybridization of Human Carcinomas. Ma H (ed). Elsevier Academic Press, Burlington, pp237-243, 2005.
33. Ishiwata T, Friess H, Buchler MW, Lopez ME and Korc M: Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. Am J Pathol 153: 213-222, 1998.
34. Kawamoto M, Ishiwata T, Cho K, et al: Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. Hum Pathol 40: 189-198, 2009.
35. Naito Z, Ishiwata T, Kurban G, et al: Expression and accumulation of lumican protein in uterine cervical cancer cells at the periphery of cancer nests. Int J Oncol 20: 943-948, 2002.
36. Hammes LS, Tekmal RR, Naud P, et al: Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 110: 445-451, 2008.
37. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E and Spandidos DA: VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 221: 105-118, 2005.
38. Kwabi-Addo B, Ropiquet F, Giri D and Ittmann M: Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 46: 163-172, 2001.
39. Cha JY, Lambert QT, Reuther GW and Der CJ: Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 6: 435-445, 2008.
40. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW and Williams ED: Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66: 11271-11278, 2006.